Sorafenib

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26400
JPY 46800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(134)

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NHzmNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\3TWM2OD1yLkCwNFAxOzB|IN88US=> Ml7OV2FPT0WU
MONO-MAC-6 NH2xd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLXdVlKSzVyPUCuNFA1OThizszN NF\FTVlUSU6JRWK=
ALL-PO MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjiZ2dKSzVyPUCuNFMyQDRizszN MmPpV2FPT0WU
NKM-1 NUj0[3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\xbmhIUUN3ME2wMlA4PDF4IN88US=> NXXsOmZvW0GQR1XS
CGTH-W-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMkWwNlIh|ryP MmH3V2FPT0WU
BB65-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D6RWlEPTB;MD60O|A4OyEQvF2= M{jjXnNCVkeHUh?=
NOS-1 NIH5dmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrkOYdKSzVyPUCuOVY{PiEQvF2= M3XKW3NCVkeHUh?=
SH-4 NUPMfIJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLMdmVGUUN3ME2wMlY2PjF|IN88US=> NHXm[nVUSU6JRWK=
HOP-62 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOEWwPFgh|ryP NX7jZVhHW0GQR1XS
HCC2998 M1TCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknyTWM2OD1yLki4PFE5KM7:TR?= NEHKRohUSU6JRWK=
GDM-1 M4DEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHez[ppKSzVyPUCuPVA3QThizszN M33BR3NCVkeHUh?=
KM12 M3faeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP0TWM2OD1zLkCyNFk5KM7:TR?= MXvTRW5ITVJ?
LB2518-MEL NIXhdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDQTWM2OD1zLkKwPFA6KM7:TR?= MUTTRW5ITVJ?
NCI-H1436 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrxTWM2OD1zLkKxOlc5KM7:TR?= NF\YRVlUSU6JRWK=
EM-2 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD4TWM2OD1zLkO1OVc5KM7:TR?= MnfJV2FPT0WU
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwM{e2OFgh|ryP MUPTRW5ITVJ?
KG-1 M2f5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfoc4lKSzVyPUGuOFc6OzVizszN M3T2ZXNCVkeHUh?=
A388 NGXTdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTCTWM2OD1zLkW5NVY2KM7:TR?= M2PPNnNCVkeHUh?=
no-10 M1m3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwNkG3NlYh|ryP NUfYRXY6W0GQR1XS
SF126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TrOGlEPTB;MT62N|gyOiEQvF2= M4XNTHNCVkeHUh?=
MEG-01 M{C4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvGUYlKSzVyPUGuPFA6QCEQvF2= NVn1eGJqW0GQR1XS
A3-KAW M2XRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHzenFKSzVyPUGuPFg1OiEQvF2= M1HZPXNCVkeHUh?=
D-247MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3U[YtKSzVyPUKuNVQ1QCEQvF2= MmPLV2FPT0WU
OVCAR-4 NIHLXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvuNmN5UUN3ME2yMlIyOzl|IN88US=> NIXMfZFUSU6JRWK=
NCI-SNU-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwM{G2NkDPxE1? NWnqcJdPW0GQR1XS
NCI-H2171 Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;0TnRKSzVyPUKuN|k4PjRizszN NXT1cplCW0GQR1XS
SIG-M5 NEnXZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjQT|JFUUN3ME2yMlQzOjR{IN88US=> MVzTRW5ITVJ?
BE-13 M{jXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnZ[oNbUUN3ME2yMlY6PjB7IN88US=> M3L6[3NCVkeHUh?=
K052 NYTTcJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor0TWM2OD1{Lke0OlE3KM7:TR?= NH\KSFdUSU6JRWK=
L-540 M2frOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr2TWM2OD1{Lke1O|g6KM7:TR?= NHGw[ZdUSU6JRWK=
KMOE-2 M4\jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDlZ5BKSzVyPUKuPFE{PSEQvF2= NYLWXmN4W0GQR1XS
MFH-ino MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHtVZpKSzVyPUKuPVIyQDVizszN MVPTRW5ITVJ?
HL-60 NUfwR41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNwME[yPVkh|ryP M4\QV3NCVkeHUh?=
HCC2218 NWC4WZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfid2pKSzVyPUOuNVIxODNizszN MX;TRW5ITVJ?
TE-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTNwMUOxOlIh|ryP NX;SfndlW0GQR1XS
MZ1-PC MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj0TWM2OD1|LkS3OVA6KM7:TR?= NIWzO5VUSU6JRWK=
MRK-nu-1 NEPWcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37WdWlEPTB;Mz62NVQ3QCEQvF2= MonPV2FPT0WU
MZ7-mel M{npTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ifHJKSzVyPUOuOlYxQTlizszN MofYV2FPT0WU
BC-1 NVH0WlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTNwN{SwNkDPxE1? M2e0RnNCVkeHUh?=
ST486 M3mxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvubFdKSzVyPUOuPFM3PzNizszN MnLwV2FPT0WU
KS-1 NGPwdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwOEixPVgh|ryP M1W4[nNCVkeHUh?=
SK-NEP-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXW[oZKSzVyPUSuNVY5OTVizszN MXTTRW5ITVJ?
BC-3 M4HQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjpVGw2UUN3ME20MlI{OzlzIN88US=> NXSzOZMzW0GQR1XS
NCI-H1581 M1S4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwMki3PVgh|ryP MlL5V2FPT0WU
MHH-PREB-1 NWX4XGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHrTWM2OD12LkSwOFg1KM7:TR?= NHz5d45USU6JRWK=
NOMO-1 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[1ZXZCUUN3ME20MlQ5QTB3IN88US=> Mk\1V2FPT0WU
QIMR-WIL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLiTWM2OD13LkC3Nlk1KM7:TR?= M2Sw[HNCVkeHUh?=
SF539 NHjSbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnYSoVPUUN3ME21MlE{OjJ5IN88US=> NF\ucmZUSU6JRWK=
TE-12 M2\oNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGNmlEPTB;NT6yOFkzQSEQvF2= NUXXVI5yW0GQR1XS
NCI-H510A MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzZUpJ3UUN3ME21MlQyPjh3IN88US=> M33Je3NCVkeHUh?=
JAR M4LVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPsRXl1UUN3ME21MlUxQDJ2IN88US=> MlzZV2FPT0WU
no-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfySFBqUUN3ME21Mlc{PTZ6IN88US=> MmfmV2FPT0WU
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\tdWZzUUN3ME21Mlk2Pjh{IN88US=> NH3YOYNUSU6JRWK=
SR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnN[HRKSzVyPU[uNFA3PzhizszN NXO4fIM3W0GQR1XS
MOLT-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPYTWM2OD14LkK1NlY3KM7:TR?= NGKyOnZUSU6JRWK=
MZ2-MEL NVP0fmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17R[2lEPTB;Nj6zNVg{QSEQvF2= M125S3NCVkeHUh?=
SW954 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXJVoVKSzVyPU[uOFU5PjZizszN NVrUWVNrW0GQR1XS
ML-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm4eI4{UUN3ME22MlUzQDR7IN88US=> MYLTRW5ITVJ?
OCI-AML2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnKVlRKSzVyPU[uOlExPjJizszN MVjTRW5ITVJ?
SIMA MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTdwMECxNFEh|ryP NYXl[INmW0GQR1XS
DOHH-2 NW\iZnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwMEW2O|Yh|ryP M1nwcnNCVkeHUh?=
697 MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X6cWlEPTB;Nz6wOVk5QSEQvF2= M3PEc3NCVkeHUh?=
NB1 NX3GemRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz6bVVKSzVyPUeuOFA1ODdizszN NXniOZpmW0GQR1XS
D-392MG MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPqTWM2OD15Lk[yOlY{KM7:TR?= NHy3T5VUSU6JRWK=
ES8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr0S5dKSzVyPUeuO|Y2ODNizszN NIXCdGdUSU6JRWK=
RPMI-8226 NWfZW|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnDUJhKSzVyPUeuPFQ2OTFizszN NUTEcHVCW0GQR1XS
IST-MEL1 NV34WVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRThwNECwNFIh|ryP NVTvdYNbW0GQR1XS
NB14 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRThwNkOxN|Mh|ryP MYDTRW5ITVJ?
HD-MY-Z M{jVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPzbnFKSzVyPUiuOlM4PDZizszN NFvtSVJUSU6JRWK=
TE-10 NYfLSmxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXmdXJXUUN3ME24Mlc3OzV|IN88US=> M4exTHNCVkeHUh?=
LC-1F MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf6R4RKSzVyPUmuNVA5OzRizszN NWW2WnlyW0GQR1XS
OS-RC-2 NF7YPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnwdVZkUUN3ME25MlEyOjR|IN88US=> MXjTRW5ITVJ?
NCI-SNU-16 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTlwMkGwNlYh|ryP MmrDV2FPT0WU
SHP-77 NV31Zo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\RTWM2OD17LkexOlYzKM7:TR?= MornV2FPT0WU
A4-Fuk MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjuTWM2OD17Lke1OlEh|ryP NIf0XndUSU6JRWK=
NB6 NXjWbVZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;h[mlEPTB;OT63OlAzQSEQvF2= MVXTRW5ITVJ?
JiyoyeP-2003 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m1WWlEPTB;MUCuOFc1PSEQvF2= NFvwR3lUSU6JRWK=
DMS-114 NFLXc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH70W|ZKSzVyPUGwMlU1PDFizszN MmPIV2FPT0WU
NB7 NWPQcnlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCSWJRUUN3ME2xNE44PTJ4IN88US=> NWKwVmZjW0GQR1XS
NCI-H747 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFzLkGyNVYh|ryP NELLO3NUSU6JRWK=
HH MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFzLkO4O|Yh|ryP NVrqWW1ZW0GQR1XS
EW-18 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFzLkmwOFQh|ryP M3z6OHNCVkeHUh?=
CHP-126 NHTjbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rBUmlEPTB;MUGuPVc{QCEQvF2= M{DJcHNCVkeHUh?=
NTERA-S-cl-D1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF{LkCyO|gh|ryP M2r2[3NCVkeHUh?=
DEL NUPxPZljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nvNGlEPTB;MUKuNFk5PSEQvF2= M1vseXNCVkeHUh?=
LU-139 M3TRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr0blRKSzVyPUGyMlU1OTNizszN MnrxV2FPT0WU
P30-OHK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF{LkW0O|kh|ryP NXPXbYJQW0GQR1XS
NCI-H1522 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mxW2lEPTB;MUKuO|Q3KM7:TR?= Mo\4V2FPT0WU
NCI-H1299 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF|LkK5NVEh|ryP MX;TRW5ITVJ?
UACC-257 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjUTWM2OD1zMz61NVI3KM7:TR?= Mlj4V2FPT0WU
Calu-6 NH3kdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K5RmlEPTB;MUOuOlA1PiEQvF2= NFz4ZpBUSU6JRWK=
NCI-H1882 M3;JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQUYpKSzVyPUGzMlg2PTVizszN NV7vSXptW0GQR1XS
BB30-HNC NWjYTm9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYeyN3NzUUN3ME2xOE4xPjB7IN88US=> M4XNdXNCVkeHUh?=
ES1 NXyzZWlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF2LkG1OVEh|ryP MV7TRW5ITVJ?
NCI-H1694 NITCPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5VIg1UUN3ME2xOE41QDFzIN88US=> NWH5NWM5W0GQR1XS
IST-SL1 NVLvUmpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyTWM2OD1zND65OlE3KM7:TR?= NYjlemg5W0GQR1XS
ECC4 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PuOWlEPTB;MUWuNFU2QCEQvF2= MlrGV2FPT0WU
MDA-MB-134-VI NUPzSVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDFNXBtUUN3ME2xOU41OTNzIN88US=> NETUUJhUSU6JRWK=
SCH NUXSU|BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ISmlEPTB;MUWuOFczQCEQvF2= MlPjV2FPT0WU
SK-N-FI M3TxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfYTWM2OD1zNT62OVM1KM7:TR?= MmjxV2FPT0WU
HDLM-2 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrEdo1KSzVyPUG2MlA4OTRizszN MoXRV2FPT0WU
Ramos-2G6-4C10 NHXSSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;3S4hKSzVyPUG2MlEzQTdizszN M3nDfnNCVkeHUh?=
EW-24 M4HLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF4LkG2OlEh|ryP MmjwV2FPT0WU
NCI-H2141 M1PKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:5TWM2OD1zNj6xPFkh|ryP NIXoVYpUSU6JRWK=
LC4-1 NVTOfHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPtcZNKSzVyPUG2MlYyOTlizszN NILQ[G1USU6JRWK=
HT-144 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LkOWlEPTB;MUeuNFA3KM7:TR?= NWfrZlA5W0GQR1XS
SK-MEL-1 M2PROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e5VWlEPTB;MUeuNFA4OiEQvF2= NEnsUFdUSU6JRWK=
SCC-15 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHpTWM2OD1zNz6xOlM5KM7:TR?= NF;tfJZUSU6JRWK=
C8166 M{na[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6wTWM2OD1zNz62PFM{KM7:TR?= NUPZbYM3W0GQR1XS
GOTO NXXqN3VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu0XnR{UUN3ME2xO{45OzR2IN88US=> M17ocXNCVkeHUh?=
COR-L279 NGTnW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF6LkGzOlIh|ryP MUHTRW5ITVJ?
K-562 NYnzRYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF6LkexOFMh|ryP NVXpWIp3W0GQR1XS
ES3 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\2OXNKSzVyPUG4MlgxPDFizszN MmHIV2FPT0WU
LU-165 M1LsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLQNZNJUUN3ME2xPU44ODB6IN88US=> MkezV2FPT0WU
KM-H2 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W2XGlEPTB;MkCuN|E5PCEQvF2= Mn[0V2FPT0WU
RL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LoTWlEPTB;MkCuPVY6OiEQvF2= NUfrRZhVW0GQR1XS
EW-3 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJzLkG4PFkh|ryP NHjW[GhUSU6JRWK=
A101D M{\ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XrfWlEPTB;MkGuN|c2OiEQvF2= NFfRUm9USU6JRWK=
HUTU-80 NWWyXnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXFblNrUUN3ME2yNU4{QTR4IN88US=> NY\hepVoW0GQR1XS
NCI-H23 MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX3TWM2OD1{MT6zPVkzKM7:TR?= MnjHV2FPT0WU
PF-382 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq5TWM2OD1{MT60OFA{KM7:TR?= M2[xenNCVkeHUh?=
LB373-MEL-D NGmzSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzWdYpIUUN3ME2yNU42PjF3IN88US=> NWPqeWNYW0GQR1XS
TE-8 NFPWUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qzc2lEPTB;MkGuOlM6PCEQvF2= MnrUV2FPT0WU
TE-9 NXLFeY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1UnhKSzVyPUKxMlg2OTNizszN NE[2b3VUSU6JRWK=
Daudi NIrYTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJzLkmzNFQh|ryP MoO4V2FPT0WU
D-542MG NHPTRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X5d2lEPTB;MkKuNFI2PiEQvF2= M4DTOXNCVkeHUh?=
U-698-M NIDGWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fuNWlEPTB;MkKuOFYxOyEQvF2= NYHFfWxmW0GQR1XS
ES6 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf4TWM2OD1{Mj63N|Y3KM7:TR?= Mlq0V2FPT0WU
DU-4475 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\zdGlEPTB;MkOuPFg6PyEQvF2= NX\FS2dsW0GQR1XS
ECC12 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\mTWM2OD1{ND6yPFA{KM7:TR?= MYrTRW5ITVJ?
C2BBe1 NIXKboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64TWM2OD1{ND6zNlM6KM7:TR?= M4HnR3NCVkeHUh?=
IST-SL2 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETIV4lKSzVyPUK0MlQ{PjJizszN M{fYTnNCVkeHUh?=
DJM-1 NHryfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL6TWM2OD1{ND61NlIyKM7:TR?= MoSxV2FPT0WU
DMS-153 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4[nhkUUN3ME2yOE45PjF2IN88US=> NHvXT2lUSU6JRWK=
NB13 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDkPZZyUUN3ME2yOU4xOjZ3IN88US=> MYLTRW5ITVJ?
SK-N-DZ MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;UTWM2OD1{Nj6zOFE1KM7:TR?= MXvTRW5ITVJ?
COR-L88 M{PqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv1TWM2OD1{Nj61O|k3KM7:TR?= NVPBfZhGW0GQR1XS
LU-65 NUXlUGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrSbYRKSzVyPUK2Mlg2OzVizszN MUXTRW5ITVJ?
TGBC1TKB M3vJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;pTGlEPTB;Mk[uPVgzQCEQvF2= M33GS3NCVkeHUh?=
THP-1 M37rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ5LkKxOFEh|ryP MXzTRW5ITVJ?
ONS-76 NX7ybGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LkNmlEPTB;MkeuN|MzKM7:TR?= MVLTRW5ITVJ?
LC-2-ad M{OwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ5Lk[yN|Eh|ryP M2S5R3NCVkeHUh?=
EW-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ7LkG3OFYh|ryP MWDTRW5ITVJ?
MS-1 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\uO2lEPTB;M{CuO|I4QCEQvF2= NGToOIZUSU6JRWK=
NCI-H2227 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\Gb4ZKSzVyPUOwMlk5ODZizszN NUPzfGFoW0GQR1XS
LXF-289 NFXxO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG1THNQUUN3ME2zNU41PDl{IN88US=> MWPTRW5ITVJ?
MC116 NIjvSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3ZV4FKUUN3ME2zNk4xQDJ4IN88US=> NHTLZWFUSU6JRWK=
EVSA-T NFiy[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P3S2lEPTB;M{KuNlU5PSEQvF2= MXrTRW5ITVJ?
CTB-1 M3z1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPaT3R3UUN3ME2zN{4yOTBzIN88US=> M{H0SXNCVkeHUh?=
COLO-320-HSR MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTN|LkG2NFMh|ryP MX3TRW5ITVJ?
NCI-H2196 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G1N2lEPTB;M{OuNlU2PyEQvF2= MVrTRW5ITVJ?
LB2241-RCC Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN|LkOxN|Uh|ryP NYTJc4hrW0GQR1XS
LS-513 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLlSVBnUUN3ME2zN{45PjN6IN88US=> MX7TRW5ITVJ?
LP-1 NWHNbGxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fKc2lEPTB;M{OuPVk2PiEQvF2= MoPrV2FPT0WU
A253 NYj1XIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ftR2lEPTB;M{SuNlI6PiEQvF2= MlTBV2FPT0WU
SK-MM-2 NUP3ZWkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXjdWVKSzVyPUO0Mlk1PTFizszN MYjTRW5ITVJ?
NCI-H1963 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvkTWM2OD1|NT6zNFczKM7:TR?= NVHGT3doW0GQR1XS
MMAC-SF M2DpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTN3Lki3PFUh|ryP NGnwfpRUSU6JRWK=
LB831-BLC NXT1ZlVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW1dFR4UUN3ME2zOk4xPjV2IN88US=> NXfrd3VSW0GQR1XS
WSU-NHL NEnoUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz4cohYUUN3ME2zOk4yPjRizszN NVzIO21{W0GQR1XS
CESS MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN4LkK4OFgh|ryP M4TDNXNCVkeHUh?=
NEC8 NXT6Slh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqyVWFKSzVyPUO2MlU5OzVizszN MYrTRW5ITVJ?
KNS-42 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Ly[mlEPTB;M{euNVI{PyEQvF2= MYrTRW5ITVJ?
MHH-CALL-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWzTWM2OD1|Nz6xPFIyKM7:TR?= MVTTRW5ITVJ?
K5 NHzEbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvGXZhKSzVyPUO4MlQ{KM7:TR?= MoHFV2FPT0WU
CP66-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK5S5ExUUN3ME2zPU4xPzN|IN88US=> NV23TFJtW0GQR1XS
OPM-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTN7Lki0N|Ih|ryP MkfFV2FPT0WU
IST-MES1 M4DrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTyTWM2OD12MD6zNFk3KM7:TR?= NXjwV4psW0GQR1XS
EC-GI-10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG2OWFbUUN3ME20NU42QDB3IN88US=> NGDqRnFUSU6JRWK=
CTV-1 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTR{Lki0NFYh|ryP M4\vXXNCVkeHUh?=
DG-75 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPDTWM2OD12Mz63OVk2KM7:TR?= NHXTXYpUSU6JRWK=
KNS-81-FD M{jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;BXIt1UUN3ME20OU41ODV6IN88US=> M4jCRnNCVkeHUh?=
NCI-H82 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL0TWM2OD12NT61O|U5KM7:TR?= NXzYT3VJW0GQR1XS
RPMI-8866 M4q5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTsbphRUUN3ME20Ok4yQDd|IN88US=> M4r5dHNCVkeHUh?=
ACN NHfMOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\mR2lEPTB;NE[uOFM1KM7:TR?= NFuyfnZUSU6JRWK=
NCI-H1395 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\l[lVKSzVyPUS2MlQ4PTZizszN MV7TRW5ITVJ?
NCI-H209 M4TMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XTXmlEPTB;NEeuNVQxPSEQvF2= MVPTRW5ITVJ?
TGW M{j2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR7LkC3PVEh|ryP MYrTRW5ITVJ?
NCI-H748 M3\lXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nzWWlEPTB;NEmuOFc2OyEQvF2= NITwO4lUSU6JRWK=
EKVX MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUR2lEPTB;NEmuOlYzQCEQvF2= MV7TRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

+ 展開
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 400+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
in solvent
別名 BAY 43-9006

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03780634 Not yet recruiting Hepatocellular Carcinoma Sun Yat-sen University|Kaiping Central Hospital|Guangzhou No.12 People''s Hospital April 1 2019 Phase 2
NCT03780634 Not yet recruiting Hepatocellular Carcinoma Sun Yat-sen University|Kaiping Central Hospital|Guangzhou No.12 People''s Hospital April 1 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03644511 Recruiting Hepatocellular Carcinoma Bayer February 28 2019 --
NCT03606590 Recruiting Hepatocellular Carcinoma NovoCure GmbH|NovoCure Ltd. February 15 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Rafシグナル伝達経路

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID